

Letter to the Editor

J Epidemiol 2023;33(7):381-382

Can ChatGPT Be Considered an Author of a Medical Article?

Kazuki Ide^{1,2,3}, Philip Hawke⁴, and Takeo Nakayama⁵

Received February 7, 2023; accepted February 26, 2023; released online April 8, 2023

Copyright © 2023 Kazuki Ide et al. This is an open access article distributed under the terms of Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

The technology of generative artificial intelligence (AI) is developing rapidly, and recently there has been great interest in the chatbot ChatGPT, released by OpenAI (San Francisco, CA, USA) in November 2022. Its high performance is evidenced by the fact that it scored at or near the passing standard on the United States Medical Licensing Exam (USMLE), and its potential implementation in healthcare is now under discussion in the United States. It has also been reported to be difficult to distinguish between abstracts generated by ChatGPT and those written by humans, with scientists mistaking 32% of ChatGPT abstracts as being human produced.

These developments raise the issue of whether ChatGPT is capable of true authorship, especially as ChatGPT has already been named as a co-author of at least four scientific papers, including some in the fields of medicine and nursing. To clarify this issue, we assessed whether ChatGPT actually meets the criteria for authorship of a medical article based on the guidelines of the International Committee of Medical Journal Editors (ICMJE). The ICMJE author criteria are as follows 6:

- Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
- 2. Drafting the work or revising it critically for important intellectual content; AND
- 3. Final approval of the version to be published; AND
- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

In order to provide a timely assessment of these criteria in the rapidly changing context of AI development, the criteria were reviewed and assessed by the two specialists involved in the present research project (KI and TN), then further discussed with the other contributor (PH). The results of this analysis are shown in Table 1, outlining the extent to which ChatGPT fulfills the criteria. The table reveals that, depending on the user's prompt, ChatGPT can fulfill criteria 1 and 2, but also that ChatGPT cannot fulfill criteria 3 and 4. Of course, it is possible that the ICMJE will change its authorship criteria in response to developments in AI.

For example, as ChatGPT appears to be helpful for increasing the productivity of authors, the organization may allow the inclusion of ChatGPT as a co-author to allow readers to easily find articles that have used it. However, such changes would still not alter the fact that ChatGPT at present does not appear to be capable of thinking sufficiently independently to fulfill criteria 3 and 4, giving final approval to and being accountable for the work.

Based on these considerations, we conclude that it is inappropriate for ChatGPT to be named as an author, at least in journals that have adopted the ICMJE criteria. Nevertheless, we emphasize that it is essential for the transparency of any study using ChatGPT to clearly mention its use in the study's acknowledgments. The ICMJE may consider adding such principles to its recommendations in its "Non-Author Contributors" section. This suggestion is in line with the view of the World Association of Medical Editors that chatbots cannot be authors and that, if they are used, the paper's authors should be transparent about this usage and take responsibility for the content produced by the chatbots.

In response to our prompt "Can you be a co-author of a medical article?", ChatGPT itself gave the following answer, which is consistent with our view: "As a language model, I am not able to be a co-author of a medical article because I am not a human and do not have the ability to conduct research or contribute original ideas. However, I can assist with the writing and editing of an article. It is important to note that any information generated by me should be fact-checked and independently verified by a qualified professional before being used in any formal research or publication."

The Science Family of Journals has already gone much further than this in restricting the use of AI in the articles it will accept for publication. It recently updated its editorial policies as follows^{8,9}:

Artificial intelligence (AI) policy: Text generated from AI, machine learning, or similar algorithmic tools cannot be used in papers published in Science journals, nor can the accompanying figures, images, or graphics be the products of such tools, without explicit permission from the editors. In addition, an AI program cannot be an author of a Science journal paper. A violation of this policy constitutes scientific misconduct.

Address for correspondence. Kazuki Ide, CiDER, Osaka University, 2-8 Yamadaoka, Suita, Osaka 565-0871, Japan (e-mail: ide-k@cider.osaka-u.ac.jp, ide.kazuki.2r@kyoto-u.jp).

¹Division of Scientific Information and Public Policy, Center for Infectious Disease Education and Research (CiDER), Osaka University, Osaka, Japan

²Research Center on Ethical, Legal and Social Issues, Osaka University, Osaka, Japan

³National Institute of Science and Technology Policy (NISTEP), Tokyo, Japan

⁴School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan

⁵Department of Health Informatics, Graduate School of Medicine/School of Public Health, Kyoto University, Kyoto, Japan

Table 1. Does ChatGPT meet the authorship criteria of the International Committee of Medical Journal Editors?

Criterion number	Criterion content	Yes	No
1	Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work	1	
2	Drafting the work or revising it critically for important intellectual content	✓	
3	Final approval of the version to be published		✓
4	Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved		✓

While we think that such a strict policy will certainly help to maintain authorial transparency, we are also concerned that it may overly strict, prematurely preventing researchers from benefiting from the enhanced productivity that AI promises.

It is important for humanity to consider from an early stage how to adopt AI technologies both practically and ethically in order to creatively advance scientific research, including research in epidemiology. Such discussions would be meaningful for us to become more creative in co-creation with AI.

ACKNOWLEDGEMENTS

This work was conducted as part of "The Nippon Foundation -Osaka University Project for Infectious Disease Prevention" and was supported by the Inamori Foundation (to KI) and by a Grant-in-Aid for Early-Career Scientists from the Japan Society for the Promotion of Science (18K13110 to KI).

The authors acknowledge members of the Osaka University Research Center on Ethical, Legal and Social Issues and ChatGPT for their helpful discussion.

Ethical approval: This commentary is based exclusively on information from public sources that contain no personal information; therefore, ethical approval was not required.

Data availability statement: All data are incorporated into the

Conflicts of interest: KI received honoraria from Mimir, Inc., outside the submitted work. TN received research grants from I&H Co., Ltd., Cocokarafine Co., Ltd., and Konica Minolta Inc.; consulting fees from Otsuka Pharmaceutical Co., Ltd.; honoraria from Pfizer Japan Inc., Merck Sharp & Dohme, Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Boehringer Ingelheim Inc., Eli Lilly Japan K.K., Maruho Co., Ltd., Mitsubishi Tanabe Pharma Corp., Novartis Pharma K.K., Allergan Japan K.K., Novo Nordisk Pharma Ltd., Toa Eiyo Ltd., Dentsu Inc., and GlaxoSmithKline K.K., Abbott Japan LLC, ONO PHARMACEUTICAL CO., LTD., Alexion Pharmaceuticals, Inc., CANON MEDICAL SYSTEMS CORPORATION; stock options from Bon Bon Inc.; donations from CancerScan Inc. and YUYAMA Co., Ltd., outside the submitted work. PH has no conflicts of interest in relation to this research.

REFERENCES

- 1. ChatGPT. https://openai.com/blog/chatgpt/; Accessed 01.21.2023.
- 2. Kung TH, Cheatham M, ChatGPT, et al. Performance of ChatGPT on USMLE: Potential for AI-assisted medical education using large language models. medRxiv. 2022. https://doi.org/10.1101/2022.12.19. 22283643.
- 3. Sezgin E, Sirrianni J, Linwood SL. Operationalizing and implementing pretrained, large artificial intelligence linguistic models in the US health care system: Outlook of generative pretrained transformer 3 (GPT-3) as a service model. JMIR Med Inform. 2022;10:e32875.
- 4. Else H. Abstracts written by ChatGPT fool scientists. Nature. 2023; 613(7944):423.
- 5. Stokel-Walker C. ChatGPT listed as author on research papers: many scientists disapprove. Nature. 2023;613(7945):620-621.
- 6. ICMJE. Defining the Role of Authors and Contributors. https://www. icmje.org/recommendations/browse/roles-and-responsibilities/definingthe-role-of-authors-and-contributors.html; Accessed 01.21.2023.
- 7. WAMA. Chatbots, ChatGPT, and Scholarly Manuscripts WAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications. URL: https://wame.org/page3.php?id=106; Accessed 02.13.2023.
- 8. Science Journals: Editorial Policies. https://www.science.org/content/ page/science-journals-editorial-policies; Accessed 02.13.2023.
- 9. Thorp HH. ChatGPT is fun, but not an author. Science. 2023;379:313.